Sermorelin vs. HGH: How They Differ and Who Uses Each

Last updated November 2, 2026 · Reviewed by the Gala Health team

Quick comparison

	Sermorelin	HGH (somatropin)
What it is	A 29-amino-acid analogue of growth hormone-releasing hormone (GHRH)	Recombinant human growth hormone
How it works	Stimulates the pituitary to secrete growth hormone	Replaces growth hormone directly
FDA-approved product today	No. The brand-name product (Geref) was discontinued	Yes, for specific medical conditions
Typical route	Subcutaneous injection	Subcutaneous injection
Availability	Compounded versions only, which are not FDA-approved	Prescription, for approved uses

What sermorelin is

Sermorelin is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone, described in a pharmacology review as the shortest synthetic peptide with full GHRH biological activity. It acts on the anterior pituitary gland to stimulate growth hormone secretion.

It was once an FDA-approved drug. Geref (sermorelin acetate) was marketed by EMD Serono: the vial was indicated for idiopathic growth hormone deficiency in children, and the ampule for evaluating pituitary growth hormone secretion. The manufacturer told the FDA it was discontinuing the products in 2008, and FDA withdrew approval of both applications effective June 18, 2009. In a 2013 Federal Register notice, the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness. The notice does not state the company's specific reasons for stopping.

Today, sermorelin offered through telehealth is a compounded product. The FDA list of bulk substances nominated for compounding under section 503A (updated May 14, 2026) that we reviewed does not include sermorelin. We are not drawing a conclusion from that, other than that sermorelin should not be treated as a product with an FDA finding of safety or effectiveness for adults seeking longevity benefits.

What HGH (somatropin) is and what it is approved for

HGH, or human growth hormone, as a medicine is somatropin. Its FDA-approved labeling, for example for Genotropin, covers children with growth failure from growth hormone deficiency, Prader-Willi syndrome, small for gestational age, Turner syndrome, and idiopathic short stature, and adults with either adult-onset or childhood-onset growth hormone deficiency. It is injected subcutaneously.

The label lists contraindications that include active malignancy, acute critical illness, hypersensitivity to somatropin or its excipients, and active proliferative or severe non-proliferative diabetic retinopathy. Anti-aging, athletic performance, and general wellness are not approved uses.

How each one works

Somatropin is direct replacement: the growth hormone you inject is the hormone itself, so the dose you give sets what your body receives.

Sermorelin works one step earlier. It signals the pituitary gland to make and release growth hormone, so the output still passes through your body's own regulation. This is the main conceptual difference between the two. It does not show that sermorelin is more effective or safer for any particular goal, and we are not aware of a direct comparison trial in healthy adults.

Side effects of each

Sermorelin: in the pediatric data summarized in a published review, single intravenous doses and repeated daily subcutaneous doses were well tolerated, and the most commonly reported events were transient facial flushing and pain at the injection site. Those data come from children with growth hormone deficiency, studied decades ago, so they do not tell us the adult risk profile for long-term use.

Somatropin: the Genotropin label reports that in adult growth hormone deficiency trials the majority of adverse events were mild to moderate symptoms of fluid retention. Other common reactions include headache and injection site reactions, with peripheral swelling, arthralgia, and paresthesia reported. Warnings include decreased insulin sensitivity (glucose should be monitored), fluid retention, and carpal tunnel syndrome symptoms, which often improved with dose reduction or interruption.

For a broader look at injectable longevity risks, see our guide to NAD+ injection side effects.

Legal and regulatory status

Somatropin is a prescription drug. Federal law (21 U.S.C. 333(e)) makes it a felony to knowingly distribute human growth hormone, defined as somatrem, somatropin, or an analogue of either, for uses other than treating a disease or other recognized medical condition that is authorized by FDA and done under a physician's order.

Compounded medications are not FDA-approved. That applies to compounded sermorelin: the FDA states that it does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed.

Who might consider sermorelin

Some adults ask about sermorelin because they are interested in sleep, recovery, or athletic performance as part of a longevity plan. Evidence for those goals in healthy adults is limited, and no outcome is guaranteed.

Gala's screening excludes people under 25, and anyone with elevated prolactin or IGF-1, uncontrolled diabetes (A1C over 10%), binge drinking (4 to 5 or more drinks per occasion), opiate use, hypothyroidism or thyroid medication use, or a known allergy to sermorelin. The intake questionnaire checks these before a provider reviews your case.

Whichever option you consider, ask a provider what the evidence is for your specific goal, how progress would be measured, which pharmacy compounds the product, and which symptoms mean you should stop and call. Somatropin labeling flags blood sugar and fluid balance, and Gala's own screening asks about diabetes, thyroid history, alcohol, and opiates, so a full medication and health history matters before any growth hormone-related treatment. Be wary of any seller who promises specific results, offers growth hormone without a clinician review, or cannot tell you where the product is made.

How Gala's longevity program works

A licensed provider reviews your intake asynchronously, with no video call. If sermorelin is appropriate, it is a subcutaneous injection you give at home, typically at bedtime five nights a week, with a built-in 2-week break every 6 months. See sermorelin at Gala, the NAD+ option, or the full longevity program. To see whether you qualify, start your online longevity intake.

Frequently asked questions

Is sermorelin the same as HGH?

No. HGH (somatropin) is growth hormone itself. Sermorelin is a growth-hormone-releasing peptide that signals your pituitary gland to produce its own growth hormone. It does not introduce synthetic HGH directly.

Is sermorelin safer than HGH?

We cannot say that. The two have different side-effect profiles and have not been compared in healthy adults in a head-to-head trial that we found. Somatropin labeling lists fluid retention, insulin resistance, and carpal tunnel symptoms, while sermorelin's published tolerability data come mainly from older pediatric studies. A provider should review your history.

Is sermorelin FDA-approved?

Not currently as a marketed product. Geref, the brand-name sermorelin, was FDA-approved but discontinued by its manufacturer, and approval was withdrawn in 2009 (the FDA found this was not for safety or effectiveness reasons). Compounded medications are not FDA-approved.

Why does the protocol include a break every 6 months?

The protocol builds in a 2-week washout period every 6 months as a standard precaution to help prevent your body from developing tolerance to the signal.

How is sermorelin taken?

As a subcutaneous injection, which means under the skin. In Gala's program it is typically taken at bedtime five nights a week after a licensed provider reviews your intake and confirms it is appropriate for you.

Ready to talk to a provider?

Your answers go to a licensed provider, who decides whether treatment is right for you. Learn more about Longevity.

Start your longevity intake

Sources

This article is for general information and is not medical advice. Talk to a licensed provider about your own health.